tretinoin
Sources réglementaires consultées
Indications approuvées
- Traitement topique de l’acné vulgaire léger à modéré.
Contre-indications
Absolues
- Hypersensibilité à la trétinoïne ou aux excipients ; grossesse ou projet de grossesse.
- Antécédents personnels ou familiaux d’épithéliome cutané ; traitement par des médicaments photosensibilisants.
Mises en garde cliniques
- Mise en garde majeure · Il peut provoquer une irritation locale importante, surtout sur une peau eczémateuse ou brûlée par le soleil ; espacer ou arrêter si l’irritation persiste ou est sévère. — CIMA/AEMPS, ficha técnica 60140
- Éviter le soleil, les UVA et les lampes solaires ; utiliser un écran solaire d’au moins FPS 15 et des vêtements protecteurs. Éviter les yeux, les paupières, le nez, la bouche, les muqueuses et l’accumulation dans les plis. — CIMA/AEMPS, ficha técnica 60140
Interactions médicamenteuses
- ModéréeProduits topiques abrasifs, desséchants, desquamants ou irritants
Mécanisme: Ils peuvent augmenter l’irritation cutanée.
Recommandation: Éviter l’usage simultané sauf sous surveillance clinique ; ne pas appliquer de cosmétiques ou d’hydratants au même moment.
CIMA/AEMPS, ficha técnica 60140https://cima.aemps.es/cima/dochtml/ft/60140/FT_60140.html
- SévèreThiazidiques, tétracyclines, fluoroquinolones, phénothiazines ou sulfamides photosensibilisants
Mécanisme: Ils peuvent augmenter la phototoxicité.
Recommandation: Ne pas appliquer de trétinoïne pendant un traitement par ces médicaments photosensibilisants.
CIMA/AEMPS, ficha técnica 60140https://cima.aemps.es/cima/dochtml/ft/60140/FT_60140.html
Effets indésirables
Communs (≥1%)
Sécheresse ou desquamation cutanée · Brûlure, picotement ou prurit · Érythème · Œdème, vésicules ou croûtes · Hypo- ou hyperpigmentation transitoire
Grossesse et allaitement
Contre-indiqué pendant la grossesse et chez les femmes qui envisagent une grossesse ; arrêter en cas de grossesse. Pendant l’allaitement, utiliser uniquement si le bénéfice thérapeutique justifie le risque possible.
Bibliographie récente (PubMed)
Acne vulgaris commonly affects adults, adolescents, and preadolescents aged 9 years or older. The objective of this study was to provide evidence-based recommendations for the management of acne. A work group conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations. This guideline presents 18 evidence-based recommendations and 5 good practice statements. Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements. Analysis is based on the best available evidence at the time of the systematic review. These guidelines provide evidence-based recommendations for the management of acne vulgaris.
Acne vulgaris is an inflammatory disease of the pilosebaceous unit of the skin that primarily involves the face and trunk and affects approximately 9% of the population worldwide (approximately 85% of individuals aged 12-24 years, and approximately 50% of patients aged 20-29 years). Acne vulgaris can cause permanent physical scarring, negatively affect quality of life and self-image, and has been associated with increased rates of anxiety, depression, and suicidal ideation. Acne vulgaris is classified based on patient age, lesion morphology (comedonal, inflammatory, mixed, nodulocystic), distribution (location on face, trunk, or both), and severity (extent, presence or absence of scarring, postinflammatory erythema, or hyperpigmentation). Although most acne does not require specific medical evaluation, medical workup is sometimes warranted. Topical therapies such as retinoids (eg, tretinoin, adapalene), benzoyl peroxide, azelaic acid, and/or combinations of topical agents are first-line treatments. When prescribed as a single therapy in a randomized trial of 207 patients, treatment with tretinoin 0.025% gel reduced acne lesion counts at 12 weeks by 63% compared with baseline. Combinations of topical agents with systemic agents (oral antibiotics such as doxycycline and minocycline, hormonal therapies such as combination oral contraception [COC] or spironolactone, or isotretinoin) are recommended for more severe disease. In a meta-analysis of 32 randomized clinical trials, COC was associated with reductions in inflammatory lesions by 62%, placebo was associated with a 26% reduction, and oral antibiotics were associated with a 58% reduction at 6-month follow-up. Isotretinoin is approved by the US Food and Drug Administration for treating severe recalcitrant nodular acne but is often used to treat resistant or persistent moderate to severe acne, as well as acne that produces scarring or significant psychosocial distress. Acne vulgaris affects approximately 9% of the pop
We aimed to determine the efficacy of the various available oral, topical, and procedural treatment options for hair loss in individuals with androgenic alopecia. Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic review of the National Library of Medicine was performed. Overall, 141 unique studies met our inclusion criteria. We demonstrate that many over the counter (e.g. topical minoxidil, supplements, low-level light treatment), prescription (e.g. oral minoxidil, finasteride, dutasteride), and procedural (e.g. platelet-rich plasma, fractionated lasers, hair transplantation) treatments successfully promote hair growth, highlighting the superiority of a multifaceted and individualized approach to management.
Skin ageing is a complex process involving the additive effects of skin's interaction with its external environment, predominantly chronic sun exposure, upon a background of time-dependent intrinsic ageing. Skin health and beauty is considered one of the principal factors perceived to represent overall 'health and wellbeing'; thus, the demand for skin rejuvenation strategies has rapidly increased, with a worldwide annual expenditure expected to grow from $US24.6 billion to around $US44.5 billion by 2030 (https://www.databridgemarketresearch.com/reports/global-facial-rejuvenation-market). Skin rejuvenation can be achieved in several ways, ranging from laser and device-based treatments to chemical peels and injectables; however, topical skin care regimes are a mainstay treatment for ageing skin and all patients seeking skin rejuvenation can benefit from this relatively low-risk intervention. While the most efficacious topical rejuvenation treatment is application of tretinoin (all-trans retinoic acid) - a prescription-only medicine considered to be the clinical 'gold standard' - a hybrid category of 'cosmeceutical' products at the midpoint of the spectrum of cosmetics and pharmaceutical has emerged. This article reviews the clinical manifestations of skin ageing and the available topical treatments for skin rejuvenation, including retinoids, peptides and antioxidants. This sheet is about using topical tretinoin in pregnancy and while breastfeeding. This information is based on available published literature. It should not take the place of medical care and advice from your healthcare provider.